Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
HCW Presentation September 13, 2021
Canaccord Presentation August 12, 2021
Wedbush Presentation August 11, 2021
HCW Presentation March 9, 2021
SVB Leerink Presentation Feb 24, 2021
JPM Presentation Jan 14, 2021
Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020
Press Releases
ObsEva to Present at 2016 Wedbush Pacgrow Healthcare Conference
press release
August 10, 2016
Geneva, Switzerland, 10 August 2016 – ObsEva, a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced that Ernest Loumaye,…
Read moreObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2α Antagonist, for the Treatment of Preterm Labor
press release
July 28, 2016
Geneva, Switzerland, 28 July 2016 – ObsEva, a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to…
Read moreObsEva Receives Clearance from US FDA to Initiate Phase 2b Study EDELWEISS with OBE2109, a Potentially Best-in-Class Oral GnRH Antagonist, for the Treatment of Endometriosis
press release
July 6, 2016
Geneva, Switzerland, 06 July, 2016 – ObsEva, a Swiss biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced that its…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2023
June 29, 2023
ObsEva Annual General Meeting 2022
May 18, 2022
Upcoming Events
Sorry, there are no events available yes.
Stock Information
Latest Press Release
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a…
Read moreInvestor Contact
Media Contact
Media
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Media
Sign up for news
